Investor Presentation

Shalby/SE/2026‐27/39 August 12, 2026 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.com Sub: Investor Presentation for the quarter ended 30th June 2026 Dear Sir / Madam, We are submitting herewith Investor Presentation on financial & operational performance of the Company for the Quarter ended June 30, 2026, which will be discussed at the Investor Conference call scheduled tomorrow i.e. on August 13, 2026 at 10:30 a.m IST. The said Investor Presentation is being uploaded on website of our Company at https://www.shalby.org/investors/  Investors Presentation. You are requested to take the same on your record. Thanking you, Yours sincerely For Shalby Limited Tushar Shah Vice President & Company Secretary Mem. No: FCS‐7216 Encl.: Investor Presentation Investor Presentation Q1 FY2027 DISCLAIMER This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia,Japanoranyjurisdictionwheresuchdistributionisunlawful. ThispresentationhasbeenpreparedbyShalbyLimited(the"Company").Thesematerialsarenotforpublicationordistribution,directlyorindirectly,inorintotheUnitedStates(includingitsterritories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securitiesoftheCompanyhavenotbeenandwillnotberegisteredundertheU.S.SecuritiesActof1933,asamended,andmaynotbeofferedorsoldintheUnitedStates,exceptpursuanttoanapplicable exemptionfromregistration.NopublicofferingofanysecuritiesoftheCompanyisbeingmadeintheUnitedStates. The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offertobuyorsubscribeforanysecurities,norshallitoranypartofitformthebasisoforbereliedoninconnectionwithanycontract,commitmentorinvestmentdecisioninrelationtheretoinIndia,the UnitedStatesoranyotherjurisdiction. No personaccepts anyliabilitywhatsoeverforanylosshowsoeverarisingfromthe use ofthisdocumentorofits contents orotherwisearisinginconnectiontherewith.Theinformationsetoutherein may be subjecttoupdating, completion,revision, verification andamendment withoutnoticeandsuchinformation maychange materially.Financialinformation containedinthispresentation hasbeenderived fromtherestatedconsolidatedandstandalonefinancialstatementsoftheCompanyandhavebeenroundedofftothenextinteger,exceptpercentageswhichhavebeenroundedofftoonedecimalpoint. This presentation contains certain "forwardlooking statements". Forward‐looking statements are based oncertain assumptions and expectations of future events.Actual future performance, outcomes and results maydiffermateriallyfromthoseexpressedinforward‐lookingstatementsasaresultof anumberofrisks, uncertaintiesandassumptions.AlthoughtheCompanybelievesthatsuchforward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to updateforward-lookingstatementsortoadaptthemtofutureeventsordevelopments. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information containedtherein has been obtainedfromsourcesbelievedtobereliable,butthereis noassurancethattheinformation is accurate or complete.Neitherthe Companynor anyof itsadvisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained inthis presentation will actually be achieved. Allindustry data and projections contained inthis presentation are based on data obtained fromthe sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentationforanypurpose.Noresponsibilityorliabilitywhatsoeverisundertakenforthecontentshereof. This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developmentsmayaffecttheinformationcontainedinthispresentation,whichneithertheCompanynoritsadvisorsorrepresentativesareunderanobligationtoupdate,reviseoraffirm. AGENDA 0011 SSHHAALLBBYY GCORONSUOPLQIDUAATRETDERQLUYA ARNTDER ALNYN PUEARLF POERRMFAONRCMEANCE 0022 HSHOASLPBITYA LS TBAUNSDINAELSOSN EQUQAURATRETRELRYL YA NPDE RAFNONRUMAAL NPCEERFORMANCE SHALBY INTERNATIONAL QUARTERLY PERFORMANCE SHALBY MEDTECH QUARTERLY PERFORMANCE ABOUT SHALBY LIMITED Financials Snapshot Q1 FY27 Consolidated Total Revenue at ₹ 3,386 mn in Q1 FY27 vs ₹ 3,034 mn in Q1 FY26 Consolidated EBITDA at ₹ 490 mn in Q1 FY27 vs ₹ 485 mn in Q1 FY26 Consolidated Consolidated PBT at ₹ 197 mn in Q1 FY27 vs ₹ 227 mn in Q1 FY26 Financial Highlights Consolidated PAT at ₹ 105 mn in Q1 FY27 vs ₹ 77 mn in Q1 FY26 Consolidated Annualized ROCE stood at 6.7% Standalone Total Revenue at ₹ 2,591 mn in Q1 FY27 vs ₹ 2,422 mn in Q1 FY26 Standalone EBITDA at ₹ 478 mn in Q1 FY27 vs ₹ 524 mn in Q1 FY26 Standalone Standalone PBT at ₹ 339 mn in Q1 FY27 vs ₹ 401 mn in Q1 FY26 Financial Highlights Standalone PAT at ₹ 251 mn in Q1 FY27 vs ₹ 257 mn in Q1 FY26 Standalone Annualized ROCE stood at 9.4% Consolidated Performance Highlights – Q1 FY27 Financial Performance (in INR Mn) Total Revenue EBITDA1 & Margin 3386 3034 2955 485 490 16.0% 12.7% 14.5% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Up 11.6% Up 0.9% PBT & Margin PAT & Margin 7.5% 3.3% 5.8% 2.5% 6.2% 3.1% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Down13.1% Up36.7% 1. EBITDA includes other income Consolidated P/L & B/S – Q1 FY27 Profit & Loss Balance Sheet (INR Mn) Gross 5509 Q1 Q4 Q1 Q-o-Q Y-o-Y Particulars (INR Mn) Borrowings FY27 FY26 FY26 Growth Growth Total Revenue 3386 2955 3034 14.6% 11.6% Cash & Cash 873 Equivalents EBITDA2 490 374 485 30.9% 0.9% Net Cash/(Debt) (4636) EBITDA Margin % 14.5% 12.7% 16.0% PBT 197 96 227 105.0% (13.1%) Debt/Equity 0.46x PBT Margin % 5.8% 3.3% 7.5% ROCE1 6.7% PAT 105 185 77 (43.1%) 36.7% PAT Margins % 3.1% 6.2% 2.5% Notes: 1. ROCE= Annualized EBIT/ Average (Equity +Debt-Cash & Cash Equivalent) 2. EBITDA includes other income. Shalby Limited : Consolidated Revenue & EBITDA Breakup – Q1 FY27 Revenue (%) Revenue (in INR Mn) EBITDA (in INR Mn) Shalby Hospitals, 78.32% 2652.2 450.5 Pharma & Franchise Shalby International (PK Healthcare, 7.75% 39.2 262.3 Delhi-NCR) Shalby MedTech 13.92% 471.7 1.6 (Implant Business) Others 0.01% 0.2 (1.3) Shalby Limited 100% 3386.4 490.0 (Consolidated) Notes: 1. Includes Shalby Academy, Slaney and Griffin which is into pharmacy trading 2.Includes fellow subsidiaries in Delhi-NCR region. Financial Trends – Shalby Limited (Consolidated) Total Revenue (In INR Crs) EBITDA (In INR Crs) & Margin (%) 1168 1115 827 159 160 711 132 22% 19% 19% 21% 14% 15% FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 ROCE (%) 8% 8% FY21 FY22 FY23 FY24 FY25 FY26 SHALBY LIMITED BUSINESS VERTICALS www.shalby.org A Legend and Visionary Doctorpreneur behind Shalby Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated the “Zero Technique” that revolutionized Joint Replacement Surgery. A visionary entrepr [Showing first 8,000 characters — download PDF for full document]